173 related articles for article (PubMed ID: 18289090)
1. The medicinal chemistry of agents targeting monoacylglycerol lipase.
Viso A; Cisneros JA; Ortega-Gutiérrez S
Curr Top Med Chem; 2008; 8(3):231-46. PubMed ID: 18289090
[TBL] [Abstract][Full Text] [Related]
2. Monoacylglycerol lipase (MAGL) as a promising therapeutic target.
Gil-Ordóñez A; Martín-Fontecha M; Ortega-Gutiérrez S; López-Rodríguez ML
Biochem Pharmacol; 2018 Nov; 157():18-32. PubMed ID: 30059673
[TBL] [Abstract][Full Text] [Related]
3. Discovery and development of endocannabinoid-hydrolyzing enzyme inhibitors.
Minkkilä A; Saario S; Nevalainen T
Curr Top Med Chem; 2010; 10(8):828-58. PubMed ID: 20370710
[TBL] [Abstract][Full Text] [Related]
4. Overview of the chemical families of fatty acid amide hydrolase and monoacylglycerol lipase inhibitors.
Vandevoorde S
Curr Top Med Chem; 2008; 8(3):247-67. PubMed ID: 18289091
[TBL] [Abstract][Full Text] [Related]
5. Beyond the Direct Activation of Cannabinoid Receptors: New Strategies to Modulate the Endocannabinoid System in CNS-Related Diseases.
Chicca A; Arena C; Manera C
Recent Pat CNS Drug Discov; 2016; 10(2):122-141. PubMed ID: 27630088
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of the endocannabinoid-regulating enzyme monoacylglycerol lipase elicits a CB
Owens RA; Mustafa MA; Ignatowska-Jankowska BM; Damaj MI; Beardsley PM; Wiley JL; Niphakis MJ; Cravatt BF; Lichtman AH
Neuropharmacology; 2017 Oct; 125():80-86. PubMed ID: 28673548
[TBL] [Abstract][Full Text] [Related]
7. New insights into endocannabinoid degradation and its therapeutic potential.
Bari M; Battista N; Fezza F; Gasperi V; Maccarrone M
Mini Rev Med Chem; 2006 Mar; 6(3):257-68. PubMed ID: 16515464
[TBL] [Abstract][Full Text] [Related]
8. A review on the monoacylglycerol lipase: at the interface between fat and endocannabinoid signalling.
Labar G; Wouters J; Lambert DM
Curr Med Chem; 2010; 17(24):2588-607. PubMed ID: 20491633
[TBL] [Abstract][Full Text] [Related]
9. Crystal structure of the human monoacylglycerol lipase, a key actor in endocannabinoid signaling.
Labar G; Bauvois C; Borel F; Ferrer JL; Wouters J; Lambert DM
Chembiochem; 2010 Jan; 11(2):218-27. PubMed ID: 19957260
[TBL] [Abstract][Full Text] [Related]
10. Inhibitors of the endocannabinoid-degrading enzymes, or how to increase endocannabinoid's activity by preventing their hydrolysis.
Feledziak M; Lambert DM; Marchand-Brynaert J; Muccioli GG
Recent Pat CNS Drug Discov; 2012 Apr; 7(1):49-70. PubMed ID: 22280341
[TBL] [Abstract][Full Text] [Related]
11. The discovery of diazetidinyl diamides as potent and reversible inhibitors of monoacylglycerol lipase (MAGL).
Zhu B; Connolly PJ; Zhang SP; Chevalier KM; Milligan CM; Flores CM; Macielag MJ
Bioorg Med Chem Lett; 2020 Jun; 30(12):127198. PubMed ID: 32334914
[TBL] [Abstract][Full Text] [Related]
12. Focus on the three key enzymes hydrolysing endocannabinoids as new drug targets.
Vandevoorde S; Lambert DM
Curr Pharm Des; 2005; 11(20):2647-68. PubMed ID: 16101463
[TBL] [Abstract][Full Text] [Related]
13. Development of Thiazole-5-carboxylate Derivatives as Selective Inhibitors of Monoacylglycerol Lipase as Target in Cancer.
Ali MR; Kumar S; Shalmali N; Afzal O; Azim S; Chanana D; Alam O; Paudel YN; Sharma M; Bawa S
Mini Rev Med Chem; 2019; 19(5):410-423. PubMed ID: 29962341
[TBL] [Abstract][Full Text] [Related]
14. Set-Up and Validation of a High Throughput Screening Method for Human Monoacylglycerol Lipase (MAGL) Based on a New Red Fluorescent Probe.
Miceli M; Casati S; Ottria R; Di Leo S; Eberini I; Palazzolo L; Parravicini C; Ciuffreda P
Molecules; 2019 Jun; 24(12):. PubMed ID: 31208066
[TBL] [Abstract][Full Text] [Related]
15. A reversible and selective inhibitor of monoacylglycerol lipase ameliorates multiple sclerosis.
Hernández-Torres G; Cipriano M; Hedén E; Björklund E; Canales Á; Zian D; Feliú A; Mecha M; Guaza C; Fowler CJ; Ortega-Gutiérrez S; López-Rodríguez ML
Angew Chem Int Ed Engl; 2014 Dec; 53(50):13765-70. PubMed ID: 25298214
[TBL] [Abstract][Full Text] [Related]
16. Discovery of long-chain salicylketoxime derivatives as monoacylglycerol lipase (MAGL) inhibitors.
Bononi G; Granchi C; Lapillo M; Giannotti M; Nieri D; Fortunato S; Boustani ME; Caligiuri I; Poli G; Carlson KE; Kim SH; Macchia M; Martinelli A; Rizzolio F; Chicca A; Katzenellenbogen JA; Minutolo F; Tuccinardi T
Eur J Med Chem; 2018 Sep; 157():817-836. PubMed ID: 30144699
[TBL] [Abstract][Full Text] [Related]
17. Comparative biochemical characterization of the monoacylglycerol lipase inhibitor KML29 in brain, spinal cord, liver, spleen, fat and muscle tissue.
Pasquarelli N; Porazik C; Hanselmann J; Weydt P; Ferger B; Witting A
Neuropharmacology; 2015 Apr; 91():148-56. PubMed ID: 25497453
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and pharmacological evaluation of 2,4-dinitroaryldithiocarbamate derivatives as novel monoacylglycerol lipase inhibitors.
Kapanda CN; Masquelier J; Labar G; Muccioli GG; Poupaert JH; Lambert DM
J Med Chem; 2012 Jun; 55(12):5774-83. PubMed ID: 22651858
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of monoacylglycerol lipase and fatty acid amide hydrolase by analogues of 2-arachidonoylglycerol.
Ghafouri N; Tiger G; Razdan RK; Mahadevan A; Pertwee RG; Martin BR; Fowler CJ
Br J Pharmacol; 2004 Nov; 143(6):774-84. PubMed ID: 15492019
[TBL] [Abstract][Full Text] [Related]
20. The role of endocannabinoid pathway in the neuropathology of Alzheimer's disease: Can the inhibitors of MAGL and FAAH prove to be potential therapeutic targets against the cognitive impairment associated with Alzheimer's disease?
Bajaj S; Jain S; Vyas P; Bawa S; Vohora D
Brain Res Bull; 2021 Sep; 174():305-322. PubMed ID: 34217798
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
